Please Note: THIS FORUM IS PATIENT MODERATED AND IS NOT CONNECTED TO ANY CLINIC OR DOCTOR. IF YOU WISH TO CONTACT A CERTAIN DOCTOR OR CLINIC, PLEASE LOOK IN THE ASK THE DOCTOR SECTION FOR DOCTOR OR CLINIC PHONE NUMBERS AND EMAIL ADDRESSES.

                        Home || Contact Us || Help Registering and Participating || Disclaimer


 SeaChange now offers CBD Oil

 

Barbara and Jeannine's Book

Bea Luis Memorial

 


Results 1 to 1 of 1

Thread: Installment 26 - Ask the Doctor with David Koos PhD - Entest Biomedical/Bio-Matrix

  1. #1
    Join Date
    May 2007
    Location
    New Hampshire
    Posts
    1,979

    Default Installment 26 - Ask the Doctor with David Koos PhD - Entest Biomedical/Bio-Matrix

    Installment 26 - Ask the Doctor with David Koos PhD - Entest Biomedical/Bio-Matrix

    BACKGROUND:

    David Koos, PhD ? currently serves as Chairman & CEO of Entest BioMedical Inc. He also currently serves as Chairman & CEO of Bio-Matrix Scientific Group Inc. which is the majority owner of Entest BioMedical. Both companies are publicly traded on the OTC Bulletin Board. Entest BioMedical?s stock symbol is ENTB and Bio-Matrix? symbol is BMSN. Entest?s website is www.EntestBio.com and updates can be found on Twitter at http://twitter.com/Entest_BioMed.

    Mr. Koos has over 25 years of investment banking and venture capital experience. Over the last 10 years his primary focus has be the development of public biotechnology companies. He holds a PhD in Sociology and a DBA in Finance.


    QUESTIONS & ANSWERS

    1) I often see research for lung diseases such as emphysema employing similar techniques for lung cancer. Are the two related other than both being caused by smoking?

    Our treatment focus for COPD relates more towards emphysema and bronchitis, not really focused on cancer. COPD is a chronic degenerative disease, while cancer is a progressive disease requiring radical treatment regimens such as chemotherapy, radiation and surgery.

    2) I read your company blurb that said you are only in the process of asking for a $500,000 grant to experiment with this laser enhancement. If we can be candidates for your orphan procedure, I'm game for it if it?s soon. How does one go about applying?

    At this moment, we are still in the preclinical stage. Our laser/LED- enhanced stem cell therapy has a great safety profile. We have been focusing squarely on evaluating the efficacy and optimizations of laser/LED parameters in our preclinical studies. The purpose of this grant application is to speed up the preclinical process, and move it to next stage-- clinical trials.

    3) A child was treated for Autism/CP 6 months ago with expanded umbilical cord cells overseas. This child developed a life threatening condition, was very ill. No cause was found. The only question was that this child had stem cell treatment. There was no illness immediately after treatment with stem cells. Is it possible that the stem cells could have caused this illness after 6 months?

    We don?t really have enough information to comment on this situation. Without knowing specifics of this case it would be hard to determine the source of the disease. Currently, we are not involved with autism research.

    4) I am just excited about the fact you are working on targeting our own adult stem cells using a photoceutical delivery to the damaged areas of the lung. I think you are on to something with that. Why did you decide to go in this direction?

    We came upon the field of low-level laser therapy by accident. Our scientific team has been focusing in the area of cord blood banking and manufacturing of disposables for processing of adipose stem cells for the past 3 years. Our board has been interested in strategically refocusing the company from services-oriented into a more research-focused model. An unbiased exploration into the various degenerative conditions that may be addressed by our existing know-how led us to explore the condition of chronic obstructive pulmonary disease (COPD). As a means of increasing our probability of success in treatment of this condition, the decision was made to develop an adjuvant therapy that would augment stem cell activity. The field of low-level laser therapy attracted us because it appeared to be relatively uncharted scientific territory for which large amounts of clinical experience exist.

    5) I read in your company information that you are developing immuno-therapeutic vaccine for cancer. Can you explain to me what this is?

    The company sees advantages of stimulating immune responses to cancers so that the body can arm itself to defend against the growth of cancer cells. This is being pursued by developing devices that can be used to implant irradiated tumor cells that come from a patient's own tumor back into the patient. The cancer cells will be sequestered within the membranes of the device and therefore prevented from escaping the device. Only components of the cancer cells which are much smaller will be able to escape. The patient's immune system will be induced to recognize these components that are specific to the tumor cells and then be able to kill any tumor cells that are left in the patient. This will prevent the cancer from returning and will eliminate metastatic tumors. There are specific proteins that can be placed into the devices along with the patient's own irradiated tumor cells that help to stimulate this type of immune response. We are developing strategies of incorporating this into an overall cancer "vaccination" scheme. We hear too often of the failures of chemotherapy in patients who initially respond but develop tumors that reappear at some later time. We expect that tumor vaccines will be a wave of the future due to their effectiveness and that with more research, the terribly unpleasant side effects of chemotherapy might be avoided.

    6) Your latest press release says you are developing stem cell therapies for diabetes and other diseases as well as COPD. What other diseases are you working on? When do you foresee that a treatment for diabetes will come to be?

    In addition to our COPD and Immunotherapeutic Cancer Vaccine, we are working on methods to mitigate tissue rejection in transplantation. This methodology has applications in both stem cell transplantation and organ transplantation.

    With respect to our diabetes research, we are early stage in this area with most of our resources being focused on COPD and the Immunotherapeutic Cancer Vaccine. The methodology to mitigate tissue rejection has implications for the aforementioned primary research areas.

    7) How many treatments do you believe it will take to repair and reverse COPD? Is it painful? Will it be a procedure that can be done in a doctor?s office?

    So far we are not sure how many treatments it will take to alleviate or reverse COPD symptoms. It really depends on our clinical trial outcome. Theoretically, the treatment times will depend on the patient's disease stage, patients with later stage or more severe COPD might need more times of treatment. The therapy is not painful at all. Our potential treatment procedure is quite straightforward and simple, basically a doctor will give his COPD patient a prescription drug (a stem cell mobilizer) and have the low level laser therapy in the doctor's office.

    8) Does your technique involve medications that a patient would be required to take post treatment and possibly for the rest of their life to prevent progression of COPD?

    The other way around, if our therapy becomes available to COPD patients, a patient needs to take a stem cell mobilizer drug called Neupogen/Filgrastim (G-CSF) before or during receiving a low-level laser/LED therapy, not after the therapy.

    9) I appreciate the fact that your company is developing a treatment method for COPD that could actually reverse the disease. COPD, for the most part has been ignored and yet it is one of the major causes of death in the world today. What made you decide to take it on? Do you think the cost of treatment will be prohibitive or do you see this as something that can be used worldwide to help those that suffer from COPD.

    Expanding on our answer in question #4, we saw COPD as an under researched area impacting a substantial sector of our population. This represented a niche in which we felt we could make a difference.

    We do not think the cost of our therapy will be prohibitive; if clinically available, it could be affordable to the majority of COPD patients. We aim to provide our therapy for those that suffer from COPD around the world.

    10) Any idea of when your treatments could be available to the general public?

    There are aspects to our COPD treatment that could be available sometime within the next 24 months. A lot depends upon clinical trials and regulatory approvals. We should have our preclinical data relatively soon and will keep the public abreast of our progress through our website, press releases and forums such as Stem Cell Pioneers.

    We have recently been notified that one of our white papers has been accepted for publication in the area of COPD treatment. Once it appears in this journal we will post it on our website.
    Last edited by barbara; 03-09-2010 at 12:53 AM.
    Still Pioneering
    Had UC treatment April 5th, 2007
    Had autologous treatment March 19, 2010
    Had bone marrow and adipose stem cell treatment (autologous) June 16, 2010

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  

Copyright 2007 - 2011 Stem Cell Pioneers